PYC THERAPEUTICS LIMITED — Board/Management Information 2016

Sep 11, 2016

==> picture [38 x 33] intentionally omitted <==

Market Announcements Platform Australian Securities Exchange

• Adjunct Professor Paul Watt resigns as Chief Scientific Officer and joins Phylogica’s board as a Non-executive Director and Chief Scientific Advisor

• Paul Watt has resigned his full time executive role as Chief Scientific Officer of Phylogica to take up senior management role at Telethon Kids Institute (where Phylogica’s laboratories are located)

• As Chief Scientific Advisor, Prof Watt will continue to provide strategic scientific advice to Phylogica

• Prof Watt will continue to be involved with Phylogica’s discovery program, both as Phylogica’s Chief Scientific Advisor and also as head of the Drug Discovery Unit of the Telethon Kids Institute.

PERTH, AUSTRALIA: September 12[th] , 2016 – Phylogica Ltd (ASX: PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces the resignation of Adjunct Professor Paul Watt from full time employment as Chief Scientific Officer of the Company.

Professor Watt will transition to a part time contractual position as Chief Scientific Advisor and will also join the Phylogica board as a Non-executive Director.

Professor Watt is taking up a senior management position as Director of Research Services and Innovation at the Telethon Kids Institute (TKI), the place where Phylogica’s technology was originally developed. However within the new role Professor Watt will be retaining his appointment as head of the Drug Discovery Unit of the TKI, the scientists of which are contracted by Phylogica to carry out its drug discovery research program.

Phylogica’s Chair Ms Stephanie Unwin said that “We congratulate Professor Watt on his new appointment and look forward to continuing to work closely with him on the Phylogica board as our Chief Scientific Advisor. We expect our drug discovery program at TKI will continue to make good progress under his strategic direction and with the able management of the Director of Research and Scientific Operations, Dr Katrin Hoffmann”.

-ends-

For further information, please contact: Rudi Michelson Monsoon Communications Tel + 61 3 9620 3333 rudim@monsoon.com.au

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company’s drug discovery platform is based on its proprietary Phylomer[®] libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer[®] libraries and proprietary screening technologies. Phylogica’s alliance partners have included Roche, Genentech (a member of the Roche Group), MedImmune (the worldwide biologics arm of AstraZeneca), Pfizer, Janssen and Cubist Pharmaceuticals (subsequently acquired by Merck).

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801 www.phylogica.com Phylogica Ltd ABN 48 098 391 961